Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03603509 · ClinicalTrials.gov registry record · Phase 4
Gene Signatures of Influenza Vaccine Responses in Older Adults
A Phase 4 study of Influenza, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 241
- Enrollment target
- 1
- Study location
NCT03603509 is a Phase 4 study of Influenza that has completed, run by Mayo Clinic. The registered enrollment target is 241 participants, below the 36,802-participant average among 156 other Influenza trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03603509, a Phase 4 study of Influenza, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 241 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to better understand the immune response to the Adjuvanted Subunit flu vaccine (MF59) and the High Dose flu vaccine (HDFlu) in people 65 years of age and older. The research team will be studying why immune response diminishes as people get older in both men and women. The ultimate goal is to understand how flu immunity develops after vaccination. This information may lead to the development of more effective flu vaccines in the future.
Conditions Studied
Interventions
- DRUG Fluzone High-Dose
- DRUG Fluad Vaccine
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 241 participants |
| Start Date | 2018-08-27 |
| Est. Completion | 2019-01-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03603509
The ClinicalTrials.gov registry entry for NCT03603509 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 241 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 36,802-participant average among 156 other Influenza trials with a reported enrollment target (99% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 2 interventions - of which Fluzone High-Dose is the first listed.
NCT03603509 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT03603509 about?
NCT03603509 is a clinical study titled "Gene Signatures of Influenza Vaccine Responses in Older Adults". The purpose of this research study is to better understand the immune response to the Adjuvanted Subunit flu vaccine (MF59) and the High Dose flu vaccine (HDFlu) in people 65 years of age and older. The research team will be studying why immune response diminishes as people get older in both men and...
What is the current status of trial NCT03603509?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 241 participants. The study started on 2018-08-27. Estimated completion is 2019-01-02.
What conditions does trial NCT03603509 study?
This clinical trial studies the following conditions: Influenza.
What interventions are being tested in trial NCT03603509?
The interventions under investigation include: Fluzone High-Dose (DRUG), Fluad Vaccine (DRUG).
Who is sponsoring clinical trial NCT03603509?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03603509 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults
RECRUITING · Phase 4
-
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
RECRUITING · Phase 4
-
Bone Marrow and Peripheral Blood Immune Responses Study
RECRUITING · Phase 4
-
Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent Influenza Virus Vaccine
COMPLETED · Phase 4
-
A Study to Evaluate the Safety of HIN1 Monovalent Vaccine (MEDI3414) in Children 2 to 17 Years of Age
COMPLETED · Phase 4
-
Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.